查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010924

性與生殖健康藥品市場：2026-2032年全球市場預測（依藥物類別、作用機制、處方狀態、給藥途徑、通路及最終用戶分類）

Sexual & Reproductive Health Drugs Market by Drug Class, Mechanism Of Action, Prescription Status, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，性與生殖健康相關藥物的市場價值將達到 407.2 億美元，到 2026 年將成長到 460 億美元，到 2032 年將達到 1,002.6 億美元，複合年成長率為 13.73%。

主要市場統計數據
基準年 2025 407.2億美元
預計年份：2026年 460億美元
預測年份 2032 1002.6億美元
複合年成長率 (%) 13.73%

對塑造性與生殖健康治療市場的現代促進因素、臨床創新和不斷變化的患者期​​望進行了權威概述。

性與生殖健康（SRH）治療領域正處於一個十字路口，臨床創新、不斷變化的監管環境以及患者期望的轉變是三大因素交匯之處。避孕技術的進步、愛滋病預防策略的拓展、生育治療和荷爾蒙補充療法的進步，以及數位化醫療解決方案和不斷演進的報銷模式，都使得策略規劃的明確變得尤為迫切。為此，從製藥公司到保險公司和醫療保健系統等相關人員都在重新評估產品系列、經銷夥伴以及循證研究的優先事項，以使其與以患者為中心的護理路徑保持一致。

技術創新、不斷變化的法規和患者行為的改變如何匯聚在一起，重塑產品開發、獲取途徑和商業策略。

性與生殖健康藥物領域正經歷多重變革，這些變革正在重新定義產品價值和相關人員的參與方式。從植入式避孕藥、長效注射劑到經皮系統，藥物傳遞技術的創新日益重視藥物的持久性、便利性和用藥依從性。同時，數位健康平台和遠端醫療的發展使得遠距處方、線上諮詢和用藥依從性監測成為可能，降低了傳統的用藥門檻，並催生了新的分銷模式。

評估美國於 2025 年徵收關稅對供應鏈、採購和臨床連續性造成的廣泛影響。

美國2025年實施的關稅對性與生殖健康（SRH）療法的供應鏈、籌資策略和定價結構產生了即時的連鎖反應。依賴跨國採購活性成分、包裝材料和給藥裝置的製造商被迫重新思考籌資策略，以緩解利潤率壓力。因此，一些公司加快了供應商多元化進程，並將製造地分散在各地，以保護生產免受關稅波動的影響，並確保患者護理的連續性。

詳細的細分分析，將藥物類別、給藥途徑和分銷管道特徵與臨床、監管和商業性優先事項相匹配。

精準理解藥物細分對於應對不同藥物類別、作用機制和給藥途徑帶來的治療和商業性複雜性至關重要。檢驗不同藥物類別之間的差異，可以揭示其研發和商業化動態的差異。避孕藥包括植入式避孕藥、注射式避孕藥、子宮內避孕系統、口服避孕藥和經皮吸收貼片。即使是口服避孕藥，不同的劑型——膠囊、粉末和藥片——也會影響患者的用藥依從性和生產過程的選擇。不孕症治療藥物分為促性腺激素釋放激素類似物、促性腺激素分泌和促排卵藥，每種藥物都有其自身的臨床給藥和監測需求。用於HIV預防的抗逆轉錄病毒藥物，特別是含有恩曲他濱和替諾福韋的方案，與持續預防策略密切相關，並與公共衛生計畫相輔相成。同時，荷爾蒙療法分為雌激素途徑和黃體素途徑，其適應症包括替代療法和避孕。

區域比較分析突顯了主要全球市場的監管複雜性、分銷現實和病患行為模式。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢差異顯著，每個地區都有其獨特的監管環境、病患行為和分銷基礎設施，這些都會對策略產生重大影響。在美洲，整合式醫療模式的高普及率和成熟的私人保險市場支持了差異化給藥系統的快速發展，而公共衛生計畫則推動了愛滋病預防抗逆轉錄病毒藥物和計劃生育舉措的規模化應用。跨境貿易關係和多元化的支付方結構要求制定彈性價格設定和市場准入計劃。

深入了解領先的研發公司如何調整其產品組合創新、製造夥伴關係和證據策略，以確保臨床和商業性優勢。

在性與生殖健康治療領域，企業策略日益注重產品組合的廣度、實證實踐的敏捷性以及成熟的夥伴關係。主要企業正努力平衡對長效給藥平台（如植入和注射劑）的投資與對新一代口服和經皮製劑的投資，以滿足不同患者的偏好。為了支持這些創新，企業正在改進臨床試驗設計，引入可操作的終點指標，並納入患者報告結局指標（PRO），以簡化報銷談判並展現產品在現實世界中的價值。

為高階主管提供切實可行的建議，以加強供應鏈、證據產生和全通路分銷，從而加快招聘速度並保持市場准入。

產業領導者應採取整合式方法，將臨床創新與穩健的供應鏈和以客戶為中心的配送策略結合。優先考慮來源多元化和擴大區域製造能力，以降低關稅和地緣政治風險，同時投資於品管系統並與供應商建立良好關係，以確保產品完整性。在考慮供應側的同時，加快證據產生項目，納入真實世界數據和病患報告結果，以支持報銷談判並在不同的支付方環境中展現價值。

嚴謹的混合方法研究框架，結合對關鍵相關人員的訪談、監管分析和資料檢驗，為可操作的見解提供了支持。

本分析的調查方法結合了定性訪談、監管指南的系統性回顧以及與專有臨床和商業資料集的三角驗證，以確保獲得穩健且多角度的洞見。主要研究包括對臨床醫生、供應鏈經理、支付方和藥房經理進行結構化檢驗，以了解實際運作和不斷變化的需求。這些洞見與對監管趨勢、核准途徑和上市後監測要求的全面回顧相結合，以評估政策變化如何影響臨床實踐。

策略結論強調，要維持成長，需要證據一致性、供應鏈韌性和以病人為中心的商業化。

總之，性與生殖健康治療領域的特點是技術快速發展、監管預期不斷變化以及患者需求波動，這些因素共同帶來了機會和挑戰。對長效給藥系統、多樣化的口服和經皮製劑以及數位化用藥依從性工具的日益依賴，正在重新定義治療的價值提案。同時，貿易趨勢和區域監管差異要求建立具有韌性的供應鏈和靈活的打入市場策略，以確保患者能夠獲得治療並維持商業性可行性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 性與生殖健康藥品市場：依藥物類別分類

  • 避孕藥
    • 植入式避孕器
    • 注射式避孕藥
    • 子宮內避孕系統
    • 口服避孕藥
    • 經皮貼劑
  • 治療勃起功能障礙的藥物
  • 不孕症藥物
    • GnRH類似物
    • 促性腺激素
    • 促排卵藥物
  • 用於預防愛滋病毒感染的抗逆轉錄病毒藥物
  • 荷爾蒙療法

第9章 依作用機轉分類的性與生殖健康相關藥物市場

  • 荷爾蒙系統
  • 非荷爾蒙類

第10章：依處方狀態分類的性與生殖健康相關藥物市場

  • 非處方藥
  • 處方箋

第11章 性與生殖健康藥品市場：依給藥途徑分類

  • 注射藥物
  • 口服
    • 膠囊
    • 粉末
    • 藥片
  • 外用
  • 經皮吸收

第12章 性與生殖健康藥品市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 性與生殖健康藥品市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章 性與生殖健康藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 性與生殖健康藥品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 性與生殖健康藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國性與生殖健康藥品市場

第18章：中國性與生殖健康相關藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla EU Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theramex HQ UK Limited
  • Viatris Inc.
Product Code: MRR-434CCDA0523A

The Sexual & Reproductive Health Drugs Market was valued at USD 40.72 billion in 2025 and is projected to grow to USD 46.00 billion in 2026, with a CAGR of 13.73%, reaching USD 100.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.72 billion
Estimated Year [2026] USD 46.00 billion
Forecast Year [2032] USD 100.26 billion
CAGR (%) 13.73%

An authoritative introduction to contemporary drivers, clinical innovations, and evolving patient expectations shaping sexual and reproductive health therapeutics

The sexual and reproductive health therapeutics landscape sits at a crossroads of clinical innovation, regulatory evolution, and shifting patient expectations. Advances in contraceptive technologies, extended HIV prevention strategies, fertility interventions, and hormone replacement protocols are converging with digital health solutions and evolving reimbursement models to create renewed urgency for strategic clarity. In response, stakeholders from manufacturers to payers and health systems are re-evaluating product portfolios, distribution partnerships, and evidence generation priorities to align with patient-centered care pathways.

At the same time, demographic shifts and changing patterns of sexual behavior are reshaping demand profiles across population segments. Younger cohorts demonstrate rising interest in user-controlled methods and discreet delivery systems, while aging populations heighten demand for hormonal therapies and fertility care. Consequently, investment in formulation diversity, adherence-support technologies, and safety monitoring is becoming central to maintaining clinical relevance and competitive differentiation. This introduction sets the stage for a deeper examination of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, company strategies, and pragmatic recommendations for leaders navigating the next phase of market evolution.

How technological innovation, regulatory evolution, and shifting patient behaviors are converging to reshape product development, access, and commercial strategies

The landscape for sexual and reproductive health therapeutics is undergoing multiple, simultaneous transformations that are redefining product value and stakeholder engagement. Technological innovations in drug delivery-ranging from implantable contraceptives and long-acting injectables to transdermal systems-are increasing the emphasis on durability, convenience, and adherence. Meanwhile, the growth of digital health platforms and telemedicine is enabling remote prescribing, virtual counseling, and adherence monitoring, thereby reducing traditional access barriers and enabling new distribution models.

Regulatory trajectories are also shifting, with adaptive pathways and accelerated review mechanisms becoming more prevalent in response to unmet clinical needs. This regulatory agility is encouraging earlier lifecycle investments and closer dialogue between developers and authorities. Additionally, the integration of real-world evidence and patient-reported outcomes into regulatory dossiers is elevating the importance of post-market surveillance and continuous quality improvement. Commercially, value-based contracting and outcomes-linked pricing are gaining traction, prompting manufacturers to align clinical endpoints with payer expectations and patient-centered measures.

Finally, social and demographic forces-such as increasing contraceptive autonomy, expanded HIV prevention awareness, and the normalization of fertility interventions-are reshaping demand composition. As a result, organizations that can combine clinical differentiation with flexible distribution strategies and robust evidence programs will be best positioned to capture long-term relevance in this evolving market.

Assessing the wide-ranging supply chain, procurement, and clinical continuity effects stemming from the United States tariffs introduced in 2025

The introduction of United States tariffs in 2025 has created immediate and cascading effects across supply chains, procurement strategies, and pricing architecture for sexual and reproductive health therapeutics. Manufacturers that rely on cross-border inputs for active pharmaceutical ingredients, packaging components, and delivery devices have had to reassess sourcing strategies to mitigate margin pressure. Consequently, several firms accelerated supplier diversification and regionalized manufacturing footprints to insulate production against tariff volatility and to maintain continuity of care for patients.

Trade measures also influenced procurement decisions at the distributor and payer levels, prompting a re-evaluation of tender timelines and contractual terms to reflect increased input cost uncertainty. In certain cases, downstream stakeholders deferred non-essential pipeline launches or prioritized products with domestic supply chains to avoid exposure to tariff pass-through. From a clinical operations perspective, the tariffs have prompted more intensive scenario planning for inventory buffers and contingency distribution routes, particularly for injectable therapies and specialty contraceptives that require cold chain or specific handling.

In parallel, the tariffs accelerated strategic conversations about onshore capacity investment and public-private partnerships to secure manufacturing resilience. Policymakers responded by engaging with industry to identify critical medicines and components warranting expedited permitting or tariff relief, while manufacturers intensified bilateral negotiations with suppliers to manage lead times and cost escalation. Overall, the tariff environment in 2025 underscored the strategic imperative of supply chain transparency, flexible sourcing, and active engagement with procurement stakeholders to preserve patient access and commercial stability.

Deep segmentation intelligence that aligns drug class nuances, administration routes, and channel distinctions to clinical, regulatory, and commercial priorities

A nuanced understanding of segmentation is essential to navigate the therapeutic and commercial complexity across drug classes, mechanisms, and access pathways. Examining drug class distinctions reveals divergent development and commercialization dynamics: contraceptives encompass implantable contraceptives, injectable contraceptives, intrauterine systems, oral contraceptives, and transdermal patches; within oral contraceptives, formulation variation across capsules, powders, and tablets shapes adherence and manufacturing choices. Fertility therapies are distinguished by GnRH analogues, gonadotropins, and ovulation inducers, each with unique clinical administration and monitoring requirements. HIV prevention antiretrovirals, notably regimens including emtricitabine and tenofovir, involve sustained prophylactic strategies that intersect with public health programming, while hormonal therapies split into estrogen and progesterone pathways that serve both replacement and contraceptive indications.

Mechanism of action segmentation between hormonal and non-hormonal agents informs safety, side-effect profiles, and patient counseling, which in turn affects prescribing patterns and formulary placement. Prescription status-differentiating over-the-counter availability from prescription-only products-shapes point-of-care interactions, consumer education needs, and private-label opportunities. Route of administration considerations, spanning injectable, oral, topical, and transdermal modes with oral forms further differentiated by capsules, powders, and tablets, determine cold chain requirements, adherence considerations, and device compatibility. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy, with retail further split into chain and independent outlets, highlights divergent margin structures, promotional strategies, and partnership models. Finally, end user segmentation including clinics, home care, and hospitals, with hospitals categorized as private and public, underscores differing procurement rules, treatment protocols, and reimbursement pathways. Taken together, these segmentation lenses allow stakeholders to prioritize clinical development, optimize channel strategies, and design evidence generation that aligns with both payer expectations and patient preferences.

Comparative regional intelligence highlighting regulatory complexity, distribution realities, and patient behavior patterns across major global markets

Regional dynamics vary markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct regulatory landscapes, patient behaviors, and distribution infrastructures that materially influence strategy. In the Americas, high adoption of integrated care models and mature private pay markets support rapid uptake of differentiated delivery systems, while public health programs drive scale for HIV prevention antiretrovirals and family planning initiatives. Cross-border trade relationships and heterogenous payer mixes require adaptable pricing and market access plans.

Europe, Middle East & Africa presents a complex mosaic of regulatory harmonization efforts alongside significant variability in procurement capabilities. In many markets, centralized reimbursement decision-making and strong public sector purchasing channels favor therapies with robust health economic evidence, whereas emerging economies within the region signal demand for cost-effective, easy-to-administer solutions. Asia-Pacific demonstrates a bifurcated picture: advanced economies accelerate adoption of digitally enabled adherence tools and long-acting therapeutics, while other markets prioritize manufacturing localization, affordability, and scalable distribution through retail and hospital networks. Across all regions, culturally informed patient engagement and nuanced regulatory navigation remain prerequisites for successful market entry and sustained uptake.

Insights into how leading developers are aligning portfolio innovation, manufacturing partnerships, and evidence strategies to secure clinical and commercial advantage

Company strategies in the sexual and reproductive health therapeutics space are increasingly defined by portfolio breadth, evidence generation agility, and partnership sophistication. Leading developers are balancing investments in long-acting delivery platforms-such as implants and injectables-with next-generation oral and transdermal formulations to appeal to diverse patient preferences. To support these innovations, firms are strengthening clinical trial design with pragmatic endpoints and incorporating patient-reported outcome measures to facilitate reimbursement discussions and to demonstrate real-world value.

Strategic alliances with contract manufacturing organizations and specialized device manufacturers are becoming more common as companies seek to de-risk complex formulation launches and to accelerate time-to-market. Commercially, firms are diversifying distribution strategies to include direct-to-consumer channels, partnerships with online pharmacies, and tailored programs for clinic networks, thereby expanding reach while preserving professional oversight where clinically required. Additionally, companies are investing in post-market surveillance infrastructure and pharmacovigilance capabilities to sustain trust and comply with evolving regulatory expectations. Those that combine manufacturing resilience, evidence-led commercialization, and nimble partnership models will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for executives to fortify supply chains, evidence generation, and omnichannel distribution to accelerate adoption and preserve access

Industry leaders should pursue an integrated approach that aligns clinical innovation with resilient supply chains and customer-centric distribution strategies. Prioritize diversification of sourcing and expansion of regional manufacturing capacity to mitigate tariff and geopolitical risks, while simultaneously investing in quality management systems and supplier relationships to preserve product integrity. Parallel to supply considerations, accelerate evidence-generation programs that incorporate real-world outcomes and patient-reported measures to support reimbursement negotiations and to demonstrate value across diverse payer environments.

From a commercial perspective, develop omnichannel distribution models that blend clinic-based prescribing with online pharmacy access and targeted retail partnerships, ensuring appropriate clinical oversight for prescription-dependent therapies while expanding convenience for over-the-counter options. Embrace digital tools for adherence support, remote counseling, and pharmacovigilance to enhance patient outcomes and to gather meaningful post-launch data. Finally, pursue collaborative engagements with public health programs and payers to align product introductions with population health priorities, thereby enhancing access and creating scalable pathways for broader uptake. These coordinated actions will strengthen market resilience and accelerate adoption of clinically differentiated therapies.

A rigorous mixed-methods research framework combining primary stakeholder interviews, regulatory analysis, and data triangulation to underpin actionable findings

The research methodology underpinning this analysis combined primary qualitative interviews, systematic review of regulatory guidance, and triangulation with proprietary clinical and commercial datasets to ensure robust, multi-perspective insights. Primary research included structured interviews with clinicians, supply chain managers, payers, and pharmacy directors to capture operational realities and evolving preferences. These insights were synthesized with a comprehensive review of regulatory trends, approval pathways, and post-market surveillance requirements to assess how policy shifts interact with clinical practice.

Data triangulation involved cross-referencing public regulatory filings, clinical trial registries, and distribution channel intelligence to validate thematic findings. The approach prioritized transparency in assumptions and rigorous documentation of source provenance. Where relevant, scenario planning exercises were employed to explore the operational implications of supply chain disruptions and policy shifts, and sensitivity analyses were conducted to test the robustness of strategic recommendations under alternative market conditions. This mixed-methods framework supports actionable conclusions that are grounded in both frontline experience and documented regulatory and clinical science.

Strategic conclusions emphasizing the need for evidence alignment, supply chain resilience, and patient-centric commercialization to sustain growth

In conclusion, the sexual and reproductive health therapeutics landscape is characterized by rapid technological progress, evolving regulatory expectations, and shifting patient demand that together create both opportunity and complexity. Long-acting delivery systems, diversified oral and transdermal formulations, and increased reliance on digital adherence tools are redefining therapeutic value propositions. Concurrently, trade dynamics and regional regulatory variation necessitate resilient supply chains and adaptive market access strategies to preserve patient access and commercial viability.

Stakeholders that invest in evidence generation aligned with payer needs, build flexible manufacturing and distribution networks, and deploy patient-centric commercial models will be best positioned to sustain growth and clinical impact. As the landscape continues to evolve, continuous engagement with clinical, regulatory, and supply chain partners will be essential to translate innovation into meaningful patient outcomes while managing operational risk. The insights presented here offer a strategic foundation for organizations seeking to navigate near-term disruptions and to capitalize on long-term opportunities within this critical therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexual & Reproductive Health Drugs Market, by Drug Class

  • 8.1. Contraceptives
    • 8.1.1. Implantable Contraceptives
    • 8.1.2. Injectable Contraceptives
    • 8.1.3. Intrauterine System
    • 8.1.4. Oral Contraceptives
    • 8.1.5. Transdermal Patches
  • 8.2. Erectile Dysfunction Treatments
  • 8.3. Fertility Drugs
    • 8.3.1. GnRH Analogues
    • 8.3.2. Gonadotropins
    • 8.3.3. Ovulation Inducers
  • 8.4. HIV Prevention Antiretrovirals
  • 8.5. Hormonal Therapies

9. Sexual & Reproductive Health Drugs Market, by Mechanism Of Action

  • 9.1. Hormonal
  • 9.2. Non Hormonal

10. Sexual & Reproductive Health Drugs Market, by Prescription Status

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Sexual & Reproductive Health Drugs Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Powders
    • 11.2.3. Tablets
  • 11.3. Topical
  • 11.4. Transdermal

12. Sexual & Reproductive Health Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Sexual & Reproductive Health Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Sexual & Reproductive Health Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexual & Reproductive Health Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexual & Reproductive Health Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Sexual & Reproductive Health Drugs Market

18. China Sexual & Reproductive Health Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amneal Pharmaceuticals, Inc.
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bayer AG
  • 19.9. Cipla EU Limited
  • 19.10. Cipla Limited
  • 19.11. Dr. Reddy's Laboratories Ltd.
  • 19.12. GlaxoSmithKline plc
  • 19.13. Hikma Pharmaceuticals PLC
  • 19.14. Johnson & Johnson
  • 19.15. Lupin Limited
  • 19.16. Mayne Pharma Group Limited
  • 19.17. Merck & Co., Inc.
  • 19.18. Mithra Pharmaceuticals SA
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Sun Pharmaceutical Industries Ltd.
  • 19.22. Teva Pharmaceutical Industries Ltd.
  • 19.23. Theramex HQ UK Limited
  • 19.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)